GNPX Genprex, Inc. Stock Quote

GNPX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	17.46%	Shs Outstand	39.67M	Perf Week	5.69%
Market Cap	210.78M	Forward P/E	7.43	EPS next Y	0.60	Insider Trans	0.18%	Shs Float	33.74M	Perf Month	-8.79%
Income	-17.90M	PEG	-	EPS next Q	-	Inst Own	16.30%	Short Float	10.35%	Perf Quarter	14.95%
Sales	-	P/S	-	EPS this Y	24.00%	Inst Trans	1.85%	Short Ratio	2.30	Perf Half Y	20.22%
Book/sh	0.78	P/B	5.72	EPS next Y	116.30%	ROA	-68.90%	Target Price	-	Perf Year	106.48%
Cash/sh	0.58	P/C	7.72	EPS next 5Y	-	ROE	-70.10%	52W Range	1.95 - 7.72	Perf YTD	7.47%
Dividend	-	P/FCF	-	EPS past 5Y	-50.20%	ROI	-	52W High	-42.23%	Beta	-
Dividend %	-	Quick Ratio	61.50	Sales past 5Y	-	Gross Margin	-	52W Low	128.72%	ATR	0.42
Employees	12	Current Ratio	68.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.31	Volatility	9.79% 8.15%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	5.90%	Profit Margin	-	Rel Volume	0.76	Prev Close	4.87
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.52M	Price	4.46
Recom	2.00	SMA20	-4.74%	SMA50	-15.33%	SMA200	11.50%	Volume	1,171,593	Change	-8.42%

Jan-26-21

Initiated

National Securities

Buy

Apr-29-19

Initiated

Noble Capital Markets

Outperform

Apr-05-21 08:30AM	Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean Business Wire
Mar-30-21 08:30AM	Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting Business Wire
Mar-24-21 08:30AM	Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29 Business Wire -5.15%
Mar-01-21 08:30AM	Genprex to Participate in Upcoming March Investor Conferences Business Wire
Feb-09-21 08:30AM	Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants Business Wire -13.43%
07:27AM	Inspect the Fingerprints on the Genprex Offering, Before Making a Move TheStreet.com
Feb-08-21 03:30PM	Genprex Announces Formation of Clinical Advisory Board Business Wire +22.72%
08:35AM	Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing PR Newswire
Feb-04-21 08:30AM	Genprex Recognizes World Cancer Day Business Wire +9.95%
Feb-01-21 01:30PM	Genprex Issues Shareholder Letter and Provides Corporate Update Business Wire +8.28%
Jan-28-21 08:35AM	Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th PR Newswire
Jan-27-21 08:30AM	Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 Business Wire -6.78%
Jan-21-21 08:30AM	Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo Business Wire
Jan-14-21 08:30AM	Genprex to Present at NobleCon17 on January 19 Business Wire
Jan-13-21 09:00AM	Genprex Achieves Major Manufacturing Milestone for REQORSA Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer Business Wire
Dec-24-20 01:02PM	Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants Business Wire -14.88%
Dec-23-20 12:40PM	Let's Look at the Big Picture of Genprex TheStreet.com +23.27%
Dec-22-20 01:15PM	Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants Business Wire +12.31%
12:10PM	Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer Benzinga
09:32AM	Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer Business Wire
Dec-17-20 08:47AM	Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session Zacks
Dec-08-20 08:16AM	Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy Business Wire
Dec-03-20 08:17AM	Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Business Wire
Nov-30-20 02:05PM	Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Business Wire
Nov-24-20 09:30AM	Diamond Equity Research 2020 Virtual Emerging Growth Invitational ACCESSWIRE
08:16AM	Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 Business Wire
Nov-11-20 08:16AM	Genprex to Participate in Panel at Life Sciences Summit on November 17 Business Wire
Nov-10-20 08:17AM	Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD Business Wire
Oct-30-20 08:17AM	Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer Business Wire -7.93%
Oct-29-20 08:16AM	Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer Business Wire +14.24%
Oct-26-20 08:16AM	Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing Business Wire
Oct-07-20 08:17AM	Genprex to Present at Zooming with LD Micro on October 14, 2020 Business Wire +5.40%
Oct-06-20 08:16AM	Genprex to Present at the Alliance for Regenerative Medicines Virtual Cell and Gene Meeting on the Mesa Business Wire
Sep-21-20 08:17AM	Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing Business Wire -5.00%
Sep-09-20 04:25PM	This Biotech Appears to Have the Right Formula for Investors TheStreet.com
Sep-02-20 05:36PM	LD Micro 360 Companies Set to Present this Week. ACCESSWIRE
08:17AM	Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs Business Wire
Aug-26-20 08:17AM	Genprex to Present at The LD 500 Virtual Conference Business Wire -6.31%
08:17AM	Genprex to Present at The LD 500 Virtual Conference ACCESSWIRE
Aug-05-20 03:34PM	LD Micro-Announces Preliminary List of Presenters for the LD 500. ACCESSWIRE
Jul-31-20 08:17AM	Genprex to Present at Proactives One2One Virtual Investor Forum on August 4, 2020 Business Wire
Jul-30-20 08:16AM	Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show" Business Wire
Jul-21-20 12:58PM	Sometimes, Stories Do Come True TheStreet.com +10.00%
08:17AM	National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex Business Wire
Jun-29-20 08:16AM	Genprex Added to Russell 3000® Index Business Wire
Jun-25-20 08:17AM	Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate Business Wire
Jun-24-20 08:16AM	Genprex CEO to Interview Live on "The Big Biz Show" Business Wire +17.42%
Jun-16-20 08:17AM	Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex Clinical Development Business Wire
Jun-09-20 08:17AM	Genprex Scheduled to Join Russell 3000® Index Business Wire +9.80%
Jun-08-20 08:17AM	Genprex to Present at the MoneyShow June Virtual Event Business Wire
May-28-20 08:17AM	Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises Business Wire
May-05-20 01:00PM	Genprex Is Soaring - And There's a One Word Reason Why TheStreet.com +51.52%
08:17AM	Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies Business Wire
May-04-20 08:17AM	Genprex Issues April 2020 Shareholder Letter Business Wire
Apr-21-20 08:17AM	Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations Business Wire
Mar-24-20 08:17AM	Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders Business Wire +27.31%
Mar-23-20 08:17AM	Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives Business Wire -9.56%
Mar-05-20 08:05AM	Lead Researcher Behind Genprexs Diabetes Gene Therapy Featured in New Video Interview Business Wire -7.30%
Mar-04-20 08:00AM	Genprex to Present at the 2020 LD Micro Virtual Conference ACCESSWIRE
Mar-03-20 08:17AM	Genprex to Present at the 2020 LD Micro Virtual Conference Business Wire -7.13%
Feb-21-20 04:15PM	Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants Business Wire +21.69%
Feb-20-20 10:22AM	Those Golden Rule TheStreet.com +12.31%
Feb-19-20 09:23AM	Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants Business Wire -20.41%
08:05AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPX Benzinga
Feb-11-20 08:17AM	Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes Business Wire +29.84%
Feb-06-20 08:17AM	Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire -6.99%
Feb-05-20 09:00AM	Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) Business Wire
Feb-03-20 08:17AM	Genprex to Present at NobleCon16 Investor Conference Business Wire -7.18%
Jan-29-20 08:18AM	Independent Researchers Find Genprexs TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy Business Wire +23.44%
Jan-28-20 08:00AM	Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering Business Wire
Jan-24-20 07:00AM	Genprex: The Bad and the Good of Capital Raises TheStreet.com -8.57%
Jan-23-20 09:00AM	Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market Business Wire -25.93%
Jan-22-20 10:54AM	Genprex's stock rallies on FDA fast-track designation MarketWatch +64.35%
Jan-21-20 08:00AM	Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer Business Wire +219.44%
Jan-06-20 08:00AM	Genprex to Present at Biotech Showcase 2020 in San Francisco Business Wire +7.44%
Nov-20-19 11:15AM	Genprex Announces $1.26 Million Registered Direct Offering Business Wire -43.55%
Nov-19-19 08:00AM	Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers Business Wire +60.29%
Nov-04-19 08:00AM	Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month Business Wire
Oct-15-19 08:00AM	MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE
Oct-09-19 08:00AM	Genprex to Present at the MicroCap Rodeo Investor Conference Business Wire -6.86%
Oct-07-19 08:00AM	Genprexs Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support Business Wire -8.00%
Sep-26-19 08:30AM	Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment GlobeNewswire
Sep-25-19 08:30AM	Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments GlobeNewswire
Sep-18-19 08:00AM	Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019 Business Wire
Sep-11-19 08:00AM	Independent Researchers Find Genprexs TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer Business Wire
Sep-07-19 04:35PM	CORRECTING and REPLACING Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
Sep-06-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments GlobeNewswire
Sep-04-19 01:43PM	Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck Business Wire
Aug-23-19 08:30AM	Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector GlobeNewswire
Aug-22-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Companys Milestone Achievements GlobeNewswire
Aug-21-19 03:31PM	What Kind Of Investor Owns Most Of Genprex, Inc. (NASDAQ:GNPX)? Simply Wall St.
08:00AM	Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference Business Wire
Aug-13-19 08:00AM	Genprex Demonstrates Growth and Expansion Through Recent Achievements Business Wire +7.29%
Aug-06-19 08:00AM	Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex Clinical Development Program Business Wire -5.85%
Jul-31-19 08:30AM	Genprex Begins Next Phase of Drug Branding Program Business Wire
Jul-09-19 01:58PM	5 Immunotherapy Stocks to Keep a Close Eye On GuruFocus.com
Jul-01-19 08:30AM	Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination with Immunotherapy for Non-Small Cell Lung Cancer Business Wire
May-31-19 08:30AM	Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Gene Therapy as Potential Cancer Treatment GlobeNewswire
May-30-19 08:35AM	Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Hunt for Gene Therapy Breakthroughs GlobeNewswire
May-21-19 08:30AM	Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum Business Wire

Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONGNECKER BRENT M	Director	Apr 05	Buy	4.15	15,000	62,250	15,000	Apr 07 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience